Friday, July 12, 2019 2:45:41 PM
__________________________________________________________________________________________________________
Patent update re: AV1066.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149346961
Greenspam3 links to new patent applications for visceral and neuropathic pain and also regulation of blood pressure:
https://patentscope.wipo.int/search/en/detail.jsf?docId=US243292967&recNum=1&office&queryString=FP%3A%28anavex%29&prevFilter&sortOption=Pub+Date+Desc&maxRec=38&fbclid=IwAR0iQoR01ea7s1UHVBUfMZG9_2CFKNXSiBIZHsMoQ7R7qQBMIbF_crtkokE
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019108653&tab=PCTBIBLIO&office&prevFilter&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&recNum=2&maxRec=38&fbclid=IwAR1R-6LmOI1qaWSmh1gixjbLF6qLMAuhqT2mS-DT173ea-5uiJId_DNz6iA
Beginning of discussion for above:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=149304398
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQB: AVXL), a clinical-stage biopharmaceutical company developing novel drug candidates to treat Alzheimer’s disease, other diseases of the central nervous system (CNS) and various types of cancer, is pleased to announce that it has been issued U.S. Patent No. 8,673,931 (the “Patent”). The composition and method Patent covers ANAVEX 3-71 (formerly AF710B) for treating Alzheimer’s disease (AD), type 2 diabetes and insulin resistance. (posted by georgejjl)
https://www.anavex.com/anavex-awarded-new-u-s-patent/
United States Patent Application January 24, 2019
NEURODEVELOPMENTAL DISORDER THERAPY
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148757220
Patent filing released 04/25/19: Anavex 2-73 for the Treatment of Cardiac Dysfunction
(from TTTav66)
https://patentscope.wipo.int/search/de/detail.jsf?docId=US241444653
Discussion here:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148457849
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148470928
Patent - ANAVEX2-73 in a method of treatment for neurodevelopmental disorders:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=148472474
AV1066 for pain an approved patent which is "ready for issue" as of 12/28/18
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145909839
Patent for specific crystaline forms of 2-73 provides extended IP protection:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145420021
Patent for Insomnia: (EN) A2-73 AS A THERAPEUIC FOR INSOMNIA, ANXIETY, AND AGITATION
Abstract:
(EN)A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10mg to about 50mg, with particular reference to about 20 to 30mg. (from basparks79)
https://patentscope.wipo.int/search/en/detail.jsf;jsessionid=173B4DDABFF25B0C26F75F5B8E98D703.wapp2nA?docId=WO2018022848&recNum=1&maxRec=13&office=&prevFilter=&sortOption=Pub+Date+Desc&queryString=FP%3A%28anavex%29&tab=PCT+Biblio
More on the patent for Insomnia:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144833903
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144834373
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144842204
Anavex, Cognision, and Ariana are doing ground breaking research in Alzheimer's disease:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145774113
December 20, 2018 Anavex & Cognision U.S. Patent Application, intermittent dosage :
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145735301
more info on Cognision in the partners post
The following posts relate to the above patent:
Tool suite used in the above patent (thanks Nidan7500):
https://www.dadm.alzdem.com/article/S2352-8729(15)00070-6/fulltext
https://www.advancedbrainmonitoring.com/
Summary of Checci patent Application:
https://investorshub.advfn.com/boards/read_msg.aspx?
ERP patent app with related organizations:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147781853
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147788179
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147668300
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147844189
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=147990271
Additional info in Anavex partners post linked at the bottom of the primary post.
Recent AVXL News
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
- May 13, 2024 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against AVXL • PR Newswire (US) • 04/26/2024 09:45:00 AM
- Contact The Gross Law Firm by May 13, 2024 Deadline to Join Class Action Against Anavex Life Sciences Corporation(AVXL) • PR Newswire (US) • 04/19/2024 09:45:00 AM
- The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 13, 2024 in Anavex Life Sciences Lawsuit - AVXL • PR Newswire (US) • 04/16/2024 09:45:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM